This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:


peer-reviewed publication

trusted source


A method for personalizing treatment for relapsed AML

medical research
Credit: Unsplash/CC0 Public Domain

A cellular profiling method called dynamic BH3 profiling (DBP), developed by investigators at Dana-Farber Cancer Institute, has the potential to help guide personalized treatment for relapsed, drug-resistant acute myeloid leukemia (AML), according to a new study published in Blood Cancer Discovery.

Using patient-derived xenograft models of AML in mice, Dana-Farber investigators, in collaboration with Shruti Bhatt, Ph.D., and researchers at the National University in Singapore, found that a reduction in the signaling involved in programmed —called mitochondrial apoptotic priming—plays a role in drug resistance alongside other factors, such as acquired .

The team treated the models with a panel of targeted medicines for AML and profiled the treated cells using DBP. The test assesses the signaling associated with cell death and provides an indicator of a drug's potential to overcome resistance. The method predicted a response to drugs in animal models of AML and in human patients.

Patients with relapsed AML have few because the disease often resists a broad range of medicines. This study shows that a cellular profiling method called DBP could provide a rapid and personalized mechanism for selecting potentially active medicines for patients. This possibility is being explored in a phase 2 prospective clinical trial at Dana-Farber that will use DBP to select therapies for patients with relapsed AML.

More information: Elyse A. Olesinski et al, Acquired Multidrug Resistance in AML Is Caused by Low Apoptotic Priming in Relapsed Myeloblasts, Blood Cancer Discovery (2024). DOI: 10.1158/2643-3230.BCD-24-0001

Journal information: Blood Cancer Discovery
Citation: A method for personalizing treatment for relapsed AML (2024, March 6) retrieved 12 June 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Combining CAR-T cells and inhibitor drugs for high-risk neuroblastoma


Feedback to editors